Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:29 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1398
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 985–996 of 1,398 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting No phase listed Observational

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

NCT06517810
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
Interventions
QUELIMMUNE (SCD-PED)
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
Up to 22 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting No phase listed Observational

The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

NCT07027306
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Osteoporotic Fractures, Osteoporosis
Interventions
Posterior stabilization (pedicle screws)
Procedure
Lead sponsor
AO Foundation, AO Spine
Other
Eligibility
50 Years and older
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Active, not recruiting Phase 2 Interventional Results available

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Active, not recruiting No phase listed Observational

Male Breast Cancer: Understanding the Biology for Improved Patient Care

NCT01101425
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 2 Interventional

A Study to Assess Anktiva in Patients With Long Covid-19.

NCT07108036
Status at this site: Recruiting
View directory record Official record
Conditions
Long COVID
Interventions
N-803 (IL-15 Superagonist)
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 2 Interventional

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

NCT04986423
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Whittier, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Active, not recruiting Phase 3 Interventional Results available

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

NCT01368588
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
454
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 2 Interventional

Imaging Immune Activation in COVID-19

NCT04815096
Status at this site: Recruiting
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Pupillometry in Identifying Risk of Postoperative Opioid-induced Respiratory Depression in Children Undergoing Tonsillectomy

NCT07573150
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Opioid-Induced Respiratory Depression, Postoperative Complications (Cardiopulmonary), Respiratory Complications Due to Anesthesia
Interventions
Infrared Pupillometry
Device
Lead sponsor
NeurOptics Inc
Industry
Eligibility
3 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Wayfinding Intervention and Long-Term Memory

NCT05625425
Status at this site: Recruiting
View directory record Official record
Conditions
Long-Term Memory Decline, Mild Cognitive Impairment
Interventions
LabyrinthVR software, Placebo Games software, Labyrinth Tablet software, Labyrinth VR wireless
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 1, 2026, 2:29 AM EST
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 1, 2026, 2:29 AM EST

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.